Juno announces complete response and corresponding early survival data for JCAR014
Juno Therapeutics announced encouraging early data for JCAR014 in patients with chronic lymphocytic leukemia who failed treatment with ibrutinib. Insights from studies of the translational product, JCAR014, are being applied to the development of JCAR017 for treatment of B-cell malignancies. December 03, 2016